Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]TQB3616 (Culmerciclib) in Healthy Chinese Subjects
NCT06149611Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration at 336 hours, Area under drug time curve at 336 hours and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06149611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149611.